Driving China’s Growth – The Pharmaceutical Industry to 2020

The Chinese Pharmaceutical market is currently the second greatest pharma market globally, in 2014 was worth $105 billion. It is forecast to increase dramatically to $200 billion by 2020 and increase its dominance as a leading player in Asia.

It is paramount for Governments to tackle not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete are analysed into key drivers, constraints, challenges and opportunities for future growth and development

The launch of PharmaCon China, 28 – 31 March 2016 is therefore timely and will co-locate Clinical Trials China, Pharma Regulatory Summit China and Pharma Compliance China to cover in-depth the issues that are affecting the drug development and research landscape!

 

Key Speakers Included:

Dr Meir-Chyun Tzou
Senior Researcher & Former Director of Division of Pharmaceutical Affairs
Taiwan Food and Drug Administration (TFDA)

Val Theisz
Director Regulatory Affairs
Medical Technology Association of Australia (MTAA)

Lingyan Li
Project Manager - Senior Pharmaceutical Affairs Scientist
Tasly Holding Group

View all speakers »

 

Why Be a Part of Pharma Regulatory Affairs China?

  • Meet Key Industry Expert Speakers and Discover In-Depth Regulation Views
  • Interactive Expert Knowledge Sharing
  • Pre and Post Conference Workshops – Apply and Adapt
  • Combined Morning Plenary Focused Forums
  • Continuous and Dedicated Networking Hours
  • Interactive Roundtable Discussions with Key Industry Experts
  • 1 Master Exhibition Zone Showcasing Leading Technology & Services

View full agenda »

 

 

Produced by  
   
Supporting Associations  
 
Media Partners   

IBC

  
International Marketing Partner